Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796052 · ClinicalTrials.gov registry record · NA
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
A NA study of Pruritus and Ichthyosis, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT03796052: Completed NA study of Pruritus and Ichthyosis, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
NCT03796052 is a NA study of Pruritus and Ichthyosis that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 53 participants, below the 107-participant average among 12 other Pruritus trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796052, a NA study of Pruritus and Ichthyosis, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the safety and efficacy of three topical agents containing oat kernel flour to determine how well they relieve skin dryness and itching related to cancer therapies. Participants will receive a body wash, a body cream, and an anti-itch balm to use at home for 4-6 weeks.
Primary Outcome
The investigator will evaluate subjects for overall xerosis (skin dryness) using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale. For xerosis, the scale ranges from 1 (dryness covering less 10% of body surface area and no associated erythema or pruritus) to 3 (dryness covering greater than 30% of body surface area and associated with itching; limits daily self care activities of daily living). A "0" grade will be used to document subjects with no presence of the CTCAE sk
Conditions Studied
Interventions
- OTHER Avena Sativa Skincare Regimen
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2019-12-18 |
| Phase | NA |
What the finished NCT03796052 record still lists
NCT03796052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 107-participant average among 12 other Pruritus trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Pruritus appearing as the primary indexed condition, and to 1 intervention - of which Avena Sativa Skincare Regimen is the first listed.
NCT03796052 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03796052 about?
NCT03796052 is a clinical study titled "Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients". This study will test the safety and efficacy of three topical agents containing oat kernel flour to determine how well they relieve skin dryness and itching related to cancer therapies. Participants will receive a body wash, a body cream, and an anti-itch balm to use at home for 4-6 weeks.
What is the current status of trial NCT03796052?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2019-05-23. Estimated completion is 2019-12-18.
What conditions does trial NCT03796052 study?
This clinical trial studies the following conditions: Pruritus, Ichthyosis.
What interventions are being tested in trial NCT03796052?
The interventions under investigation include: Avena Sativa Skincare Regimen (OTHER).
Who is sponsoring clinical trial NCT03796052?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796052 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03796052's enrollment target sits among peer trials
53 7th of 12 higher than 6 of 12 other Pruritus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pruritus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
-
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
RECRUITING · NA
-
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
RECRUITING · Phase 3
-
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
COMPLETED · Early Phase 1
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI